缬沙坦氢氯噻嗪治疗轻、中度原发性高血压的依从性观察

Effect and treatment compliance of valsartan /hydrochlorothiazide in the treatment of mild to moderate primary hypertension

目的探讨缬沙坦氢氯噻嗪治疗轻、中度原发性高血压患者的临床疗效及治疗依从性。方法将200例轻中度原发性高血压患者随机分入对照组与观察组,每组100例。对照组患者给予缬沙坦口服,观察组患者接受缬沙坦氢氯噻嗪口服,疗程为6个月。比较两组临床疗效、不良反应及治疗依从性。结果观察组治疗有效率显著高于对照组(93.0%vs.81.0%,P<0.05);观察组治疗后3个月及6个月的收缩压(SBP)及舒张压(DBP)均显著优于对照组(P<0.05);观察组治疗依从性显著优于对照组(P<0.05)。结论与缬沙坦相比,缬沙坦氢氯噻嗪治疗轻、中度原发性高血压患者的临床疗效更为理想,且安全性好,患者治疗依从性高。

Objective To explore the effectiveness and treatment compliance of valsartan/hydrochlorothiazide on the mild to moderate primary hypertension patients. Methods 200 cases of mild to moderate primary hypertension patients were randomly divided into control group and experimental group, 100 cases in each group. Control group was given valsartan treatment, and experimental group received valsartan/hydrochlorothiazide therapy. The course of treat- ment was 6 months. Clinical effect, adverse reaitions and treatment compliance were compared between the two groups. Results The treatment effective rate in experience group was much higher than that in control group （93.0% vs. 81.0% , P 〈 0. 05 ） ; SBP and DBP at 3 and 6 months after treatment in experimental group were superior to those of control group （ P 〈 0.05 ） ; treatment compliance in experimental group was superior to that of control group （ P 〈 0. 05 ）. Conclusion Compared with valsartan, valsartan/hydrochlorothiazide therapy for the mild to moderate primary hypertension patients has better effect with good safety and treatment compliance.